255 related articles for article (PubMed ID: 21685375)
41. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.
Cantor JP; Iliopoulos D; Rao AS; Druck T; Semba S; Han SY; McCorkell KA; Lakshman TV; Collins JE; Wachsberger P; Friedberg JS; Huebner K
Int J Cancer; 2007 Jan; 120(1):24-31. PubMed ID: 17019711
[TBL] [Abstract][Full Text] [Related]
42. A case of Epstein-Barr virus-negative human immunodeficiency virus-related primary effusion lymphoma.
Ota S; Fujikura Y; Yamamoto T; Maki Y; Kurokawa A; Maeda T; Kanoh S; Kawana A
J Infect Chemother; 2018 Jun; 24(6):487-491. PubMed ID: 29454632
[TBL] [Abstract][Full Text] [Related]
43. Fragile Genes That Are Frequently Altered in Cancer: Players Not Passengers.
Karras JR; Schrock MS; Batar B; Huebner K
Cytogenet Genome Res; 2016; 150(3-4):208-216. PubMed ID: 28199992
[TBL] [Abstract][Full Text] [Related]
44. Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma.
Crane GM; Xian RR; Burns KH; Borowitz MJ; Duffield AS; Taube JM
J Cutan Pathol; 2014 Dec; 41(12):928-35. PubMed ID: 25355615
[TBL] [Abstract][Full Text] [Related]
45. EBV is necessary for proliferation of dually infected primary effusion lymphoma cells.
Mack AA; Sugden B
Cancer Res; 2008 Sep; 68(17):6963-8. PubMed ID: 18757410
[TBL] [Abstract][Full Text] [Related]
46. Alterations of common chromosome fragile sites in hematopoietic malignancies.
Ishii H; Furukawa Y
Int J Hematol; 2004 Apr; 79(3):238-42. PubMed ID: 15168591
[TBL] [Abstract][Full Text] [Related]
47. Common chromosomal fragile sites and cancer: focus on FRA16D.
O'Keefe LV; Richards RI
Cancer Lett; 2006 Jan; 232(1):37-47. PubMed ID: 16242840
[TBL] [Abstract][Full Text] [Related]
48. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.
Carbone A; Cesarman E; Gloghini A; Drexler HG
AIDS; 2010 Feb; 24(4):479-90. PubMed ID: 20051807
[TBL] [Abstract][Full Text] [Related]
49. Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma.
Fassone L; Bhatia K; Gutierrez M; Capello D; Gloghini A; Dolcetti R; Vivenza D; Ascoli V; Lo Coco F; Pagani L; Dotti G; Rambaldi A; Raphael M; Tirelli U; Saglio G; Magrath IT; Carbone A; Gaidano G
Leukemia; 2000 Feb; 14(2):271-7. PubMed ID: 10673744
[TBL] [Abstract][Full Text] [Related]
50. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
51. Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8.
Carbone A; Cilia AM; Gloghini A; Capello D; Todesco M; Quattrone S; Volpe R; Gaidano G
Br J Haematol; 1998 Sep; 102(4):1081-9. PubMed ID: 9734661
[TBL] [Abstract][Full Text] [Related]
52. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models.
Karam L; Houshaymi B; Abdel-Samad R; Jaafar M; Halloum I; Pisano C; Neipel F; Darwiche N; Abou Merhi R
Oncol Rep; 2018 Feb; 39(2):721-730. PubMed ID: 29207182
[TBL] [Abstract][Full Text] [Related]
53. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ
Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827
[TBL] [Abstract][Full Text] [Related]
54. Genomic analysis of xCT-mediated regulatory network: Identification of novel targets against AIDS-associated lymphoma.
Dai L; Cao Y; Chen Y; Kaleeba JA; Zabaleta J; Qin Z
Oncotarget; 2015 May; 6(14):12710-22. PubMed ID: 25860939
[TBL] [Abstract][Full Text] [Related]
55. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines.
Gottwein E; Corcoran DL; Mukherjee N; Skalsky RL; Hafner M; Nusbaum JD; Shamulailatpam P; Love CL; Dave SS; Tuschl T; Ohler U; Cullen BR
Cell Host Microbe; 2011 Nov; 10(5):515-26. PubMed ID: 22100165
[TBL] [Abstract][Full Text] [Related]
56. Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease.
Gaidano G; Capello D; Fassone L; Gloghini A; Cilia AM; Ariatti C; Buonaiuto D; Vivenza D; Gallicchio M; Avanzi GC; Prat M; Carbone A
J Clin Virol; 2000 May; 16(3):215-24. PubMed ID: 10738140
[TBL] [Abstract][Full Text] [Related]
57. Distinct cellular origins of primary effusion lymphoma with and without EBV infection.
Hamoudi R; Diss TC; Oksenhendler E; Pan L; Carbone A; Ascoli V; Boshoff C; Isaacson P; Du MQ
Leuk Res; 2004 Apr; 28(4):333-8. PubMed ID: 15109530
[TBL] [Abstract][Full Text] [Related]
58. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
Ishii H; Mimori K; Inageta T; Murakumo Y; Vecchione A; Mori M; Furukawa Y
Mol Cancer Res; 2005 Mar; 3(3):130-8. PubMed ID: 15798093
[TBL] [Abstract][Full Text] [Related]
59. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer.
Yendamuri S; Kuroki T; Trapasso F; Henry AC; Dumon KR; Huebner K; Williams NN; Kaiser LR; Croce CM
Cancer Res; 2003 Feb; 63(4):878-81. PubMed ID: 12591741
[TBL] [Abstract][Full Text] [Related]
60. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines.
Drexler HG; Meyer C; Gaidano G; Carbone A
Leukemia; 1999 Apr; 13(4):634-40. PubMed ID: 10214873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
